News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Talon Therapeutics, Inc. (TLON.OB) Reports Third Quarter 2012 Financial Results



11/14/2012 7:25:54 AM

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2012.

"FDA accelerated approval of Marqibo® (vinCRIStine sulfate LIPOSOME injection) is Talon's most important achievement to date," stated Steven R. Deitcher, M.D., President, Chief Executive Officer and Board Member of Talon. "The patient population Marqibo® will be serving is in need of new treatment options. We are in the process of evaluating a number of paths to commercialize Marqibo®, including a potential strategic transaction, licensing agreement, or a Talon launch."

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES